These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21715253)

  • 1. [Targeting the RAS signalling pathway in cancer].
    Mansi L; Viel E; Curtit E; Medioni J; Le Tourneau C
    Bull Cancer; 2011 Oct; 98(9):1019-28. PubMed ID: 21715253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeting KRAS pathway in NSCLC therapy].
    Le Moulec S; Loriot Y; Soria JC
    Bull Cancer; 2009 Dec; 96 Suppl():S69-74. PubMed ID: 20034872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
    Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
    Martinelli E; Morgillo F; Troiani T; Ciardiello F
    Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].
    Baldini C; Duchemann B; Hollebecque A; Routier É; Varga A; Gazzah A; Bahleda R; Besse B; Soria JC; Massard C
    Bull Cancer; 2012 Sep; 99(9):865-74. PubMed ID: 25471668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress of targeted therapy related to K-ras mutation].
    Li ZW; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
    [No Abstract]   [Full Text] [Related]  

  • 7. BRAF signaling and targeted therapies in melanoma.
    Dhomen N; Marais R
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):529-45, ix. PubMed ID: 19464601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
    Thompson N; Lyons J
    Curr Opin Pharmacol; 2005 Aug; 5(4):350-6. PubMed ID: 15955734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.
    Okumura S; Jänne PA
    Clin Cancer Res; 2014 Aug; 20(16):4193-9. PubMed ID: 24907112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ras in digestive oncology: from molecular biology to clinical implications.
    Charette N; Vandeputte C; Stärkel P
    Curr Opin Oncol; 2014 Jul; 26(4):454-61. PubMed ID: 24849046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the RAS upstream and downstream signaling pathway for cancer treatment.
    Hossain MA
    Eur J Pharmacol; 2024 Sep; 979():176727. PubMed ID: 38866361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer targets in the Ras pathway.
    Rodriguez-Viciana P; Tetsu O; Oda K; Okada J; Rauen K; McCormick F
    Cold Spring Harb Symp Quant Biol; 2005; 70():461-7. PubMed ID: 16869784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK in cancer and cancer therapy.
    Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
    Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
    Delire B; Stärkel P
    Eur J Clin Invest; 2015 Jun; 45(6):609-23. PubMed ID: 25832714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.